Simulations Plus (NASDAQ:SLP) Issues FY 2025 Earnings Guidance

Simulations Plus (NASDAQ:SLP) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 1.030-1.030 for the period, compared to the consensus estimate of 0.990. The company issued revenue guidance of $79.1 million-$79.1 million, compared to the consensus revenue estimate of $78.3 million. Simulations Plus also updated its FY 2026 guidance to 1.030-1.100 EPS.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Simulations Plus in a research report on Wednesday, October 8th. William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a research note on Tuesday, July 15th. Zacks Research raised Simulations Plus to a “hold” rating in a research note on Tuesday, August 12th. BTIG Research reduced their price objective on shares of Simulations Plus from $41.00 to $25.00 and set a “buy” rating for the company in a research report on Monday, July 7th. Finally, Cowen initiated coverage on shares of Simulations Plus in a research note on Tuesday, September 30th. They issued a “hold” rating for the company. Four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Simulations Plus currently has a consensus rating of “Hold” and an average target price of $24.40.

Simulations Plus Stock Down 2.2%

NASDAQ SLP opened at $17.23 on Friday. Simulations Plus has a 52 week low of $12.39 and a 52 week high of $37.67. The business has a 50 day moving average price of $15.02 and a 200-day moving average price of $20.58. The company has a market cap of $346.79 million, a price-to-earnings ratio of -5.47 and a beta of 0.99.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. First Light Asset Management LLC acquired a new position in shares of Simulations Plus during the second quarter valued at about $6,232,000. Ameriprise Financial Inc. boosted its stake in Simulations Plus by 25.3% during the 2nd quarter. Ameriprise Financial Inc. now owns 875,447 shares of the technology company’s stock valued at $15,277,000 after purchasing an additional 176,747 shares during the last quarter. Marshall Wace LLP increased its holdings in Simulations Plus by 435.9% during the 2nd quarter. Marshall Wace LLP now owns 133,278 shares of the technology company’s stock worth $2,326,000 after purchasing an additional 108,407 shares in the last quarter. Federated Hermes Inc. raised its stake in shares of Simulations Plus by 493.4% in the second quarter. Federated Hermes Inc. now owns 66,459 shares of the technology company’s stock worth $1,160,000 after purchasing an additional 55,259 shares during the last quarter. Finally, Royal Bank of Canada lifted its holdings in shares of Simulations Plus by 26.6% in the first quarter. Royal Bank of Canada now owns 114,885 shares of the technology company’s stock valued at $2,817,000 after purchasing an additional 24,132 shares in the last quarter. 78.08% of the stock is owned by institutional investors.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.